Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations-Reference-Cited by-同舟云学术

Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations

Published:2015-11-05 Issue:1 Volume:122 Page:20-33
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Bosse Kristopher R.¹²,Maris John M.¹²

Affiliation:

1. Division of Oncology and Center for Childhood Cancer Research; Children's Hospital of Philadelphia; Philadelphia Pennsylvania

2. Department of Pediatrics, Perelman School of Medicine; University of Pennsylvania; Philadelphia Pennsylvania

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29706/fullpdf

Reference126 articles.

1. Recent advances in neuroblastoma;Maris;N Engl J Med.,2010

2. National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program SEER Database http://seer.cancer.gov 2015

3. Neuroblastoma;Maris;Lancet.,2007

4. Outcomes for children and adolescents with cancer: challenges for the twenty-first century;Smith;J Clin Oncol.,2010

5. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution;Evans;J Clin Oncol.,1996

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Defining neuroblastoma: from origin to precision medicine;Neuro-Oncology;2024-08-05

2. A comprehensive overview of liquid biopsy applications in pediatric solid tumors;npj Precision Oncology;2024-08-03

3. Neuroblastoma in children: What has changed in the 21<sup>st</sup> century;Meditsinskiy sovet = Medical Council;2024-07-25

4. Antitumor Activity of a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting LGR5 in Preclinical Models of Neuroblastoma;Pharmaceutics;2024-07-15

5. Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma;Pediatric Blood & Cancer;2024-07-05